Artiva Biotherapeutics, Inc.
ARTV
$10.79
-$0.09-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -100.00% |
| SG&A Expenses | 2.30% | 8.18% | 17.81% | 31.51% | 48.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.85% | 22.82% | 32.98% | 35.47% | 33.53% |
| Operating Income | -17.85% | -22.82% | -33.48% | -41.25% | -156.22% |
| Income Before Tax | -20.88% | -21.40% | -28.29% | -29.38% | -131.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.88% | -21.40% | -28.29% | -29.23% | -131.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.88% | -21.40% | -28.29% | -29.23% | -131.00% |
| EBIT | -17.85% | -22.82% | -33.48% | -41.25% | -156.22% |
| EBITDA | -18.20% | -23.37% | -34.48% | -42.72% | -168.03% |
| EPS Basic | -0.64% | 85.46% | 91.60% | 94.10% | 91.79% |
| Normalized Basic EPS | -0.05% | 85.21% | 91.43% | 95.24% | 93.87% |
| EPS Diluted | -0.64% | 85.46% | 91.60% | 95.35% | 95.11% |
| Normalized Diluted EPS | -0.05% | 85.21% | 91.43% | 95.24% | 94.99% |
| Average Basic Shares Outstanding | 22.98% | 43.36% | 117.74% | 357.58% | 2,742.15% |
| Average Diluted Shares Outstanding | 22.98% | 43.36% | 117.74% | 357.58% | 879.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |